national institute of biomedical imaging and bioengineering - listserv

Weekly NIH Funding Opportunities and Notices

NIH Guide for Grants and Contracts

March 15, 2019

Table of Contents (TOC)

Web Version

Notices

Notice of Special Interest: Development of Cryogenic or Other Long-term Preservation and Revival Methods for Drosophila and Zebrafish Genetic Stocks
(NOT-OD-19-089)
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
The National Institutes of Health (NIH) Office of Disease Prevention (ODP) Announces the Pathways to Prevention Workshop: Achieving Health Equity in Preventive Services
(NOT-OD-19-090) Office of Disease Prevention
Notice of Clarification Regarding the Submission of Biosketches for PA-18-906 "Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)"
(NOT-OD-19-091) National Institutes of Health
Notice of Intent to Publish a Funding Opportunity Announcement for Specialized Alcohol Research Centers (P50 Clinical trial Optional)
(NOT-AA-19-013)
National Institute on Alcohol Abuse and Alcoholism
Notice of Change to PAR-17-031 "Role of Age-Associated Metabolic Changes in Alzheimer's Disease (AD) (R01)"
(NOT-AG-19-008) National Institute on Aging
Notice of Change to PAR-18-030 "NIA Revision and Resubmission Program Project Applications (P01 Clinical Trial Optional)"
(NOT-AG-19-009) National Institute on Aging
Notice of Changes to RFA-AI-19-002 "HIV/AIDS Clinical Trials Networks Statistical and Data Management Centers (UM1 Clinical Trial Required)"
(NOT--AI-19-051)
National Institute of Allergy and Infectious Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
Notice of Availability of Administrative Supplements for Geospatial, Multilevel, and Contextual Approaches in Cancer Control and Population Sciences
(NOT-CA-19-029) National Cancer Institute
Notice of Availability of Administrative Supplements to Promote Data Sharing in Cancer Epidemiology Studies
(NOT-CA-19-031) National Cancer Institute
Notice of Special Interest: Administrative Supplements to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)
(NOT-CA-19-032) National Cancer Institute
Pre-Application Webinar for NOT-CA-19-031, Notice of Availability of Administrative Supplements to Promote Data Sharing in Cancer Epidemiology Studies
(NOT-CA-19-033) National Cancer Institute
Notice of a Joint Veterans Health Administration/National Cancer Institute Data Science Initiative called the Big Data Scientist Training Enhancement Program (BD-STEP)
(NOT-CA-19-034) National Cancer Institute
Request for Information (RFI): Needs and Challenges in Obtaining and Using Peptides for Translational and Clinical Cancer Research
(NOT-CA-19-035) National Cancer Institute
Request for Proposals (RFP) Notice: Medication Discovery Using Rat Models of Relapse
(NOT-DA-19-061) National Institute on Drug Abuse
Notice of Change in Application Due Dates for PAR-19-030 "NIDDK Education Program Grants (R25 Clinical Trial Not Allowed)"
(NOT-DK-19-011)
National Institute of Diabetes and Digestive and Kidney Diseases
Notice of NIEHS Participation on PAR-19-162 "Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)"
(NOT-ES-19-006)
National Institute of Environmental Health Sciences
Notice to early expire RFA-FD-19-007 "Conduct Studies to Establish More Targeted Durations of Use for Certain Approved Antimicrobial New Animal Drugs in Food Animals (U01 Clinical Trial Required)"
(NOT-FD-19-008) Food and Drug Administration
NIH Highlights Support for Data Science Research through the Academic Research Enhancement Award (AREA) Program
(NOT-GM-19-021)
National Institute of General Medical Sciences
National Cancer Institute
National Human Genome Research Institute
National Institute on Aging
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Library of Medicine
Notice of Special Interest: Availability of Administrative Supplements to INBRE Awards to Fund Research in Collaboration with COBRE or IDeA-CTR Awards
(NOT-GM-19-025)
National Institute of General Medical Sciences
Notice of Pre-Application Webinar for PAR-19-218 "Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34)"
(NOT-GM-19-028)
National Institute of General Medical Sciences
Notice of Special Interest: SEARCH: Stimulating ExplorAtory Research on HIV/AIDS Contribution to Heart, Lung, Blood and Sleep Comorbidities (R01 - Clinical Trial Not Allowed)
(NOT-HL-19-677)
National Heart, Lung, and Blood Institute
Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases
(NOT-HL-19-678)
National Heart, Lung, and Blood Institute
Notice of Special Interest in Research on the Health of Sexual and Gender Minority (SGM) Populations
(NOT-MD-19-001)
National Institute on Minority Health and Health Disparities
National Center for Complementary and Integrative Health
National Cancer Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
Office of Behavioral and Social Science Research Office of the Director,
NIH Office of Disease Prevention Office of Research on Women's Health
Notice of Information: Clinical Trials that Explore Non-Addictive Therapeutics for Pain Conditions under the Early Phase Pain Investigation Clinical Network (EPPIC-Net)
(NOT-NS-19-043)
National Institute of Neurological Disorders and Stroke
Request for Information: Soliciting Input on How Best to Advance Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Research
(NOT-NS-19-045)
National Institute of Neurological Disorders and Stroke
Notice of Change to Key Date for PAR-19-170 "Progression Markers for Cognitive Impairment in Parkinson's Disease Dementia (R01 Clinical Trial Not Allowed)".
(NOT-NS-19-046)
National Institute of Neurological Disorders and Stroke
Notice of Change to Key Date for PAR-19-167 "Development and Validation of Advanced Mammalian Models for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)". (NOT-NS-19-047)
National Institute of Neurological Disorders and Stroke
Notice of a Parallel Funding Opportunity Announcement by the Canadian Institutes of Health Research Institute of Neurosciences, Mental Health and Addiction (CIHR-INMHA)
(NOT-NS-19-049)
National Institute of Neurological Disorders and Stroke
New Deadline for Proposals to Collaborate with the NIH Common Fund Regenerative Medicine Programs (RMP) Stem Cell Translation Laboratory (SCTL)
(NOT-RM-19-004)
Office of Strategic Coordination (Common Fund)
Notice of Change to FOA PAR-19-100: Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional) (NOT-TR-19-017)
National Center for Advancing Translational Sciences

Requests for Applications

U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (R01 Clinical Trial Optional)
(RFA-AI-19-022)
National Institute of Allergy and Infectious Diseases
National Cancer Institute
National Institute on Alcohol Abuse and Alcoholism
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date listed below.
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (U01 Clinical Trial Optional)
(RFA-AI-19-023)
National Institute of Allergy and Infectious Diseases
National Cancer Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date listed below.
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (R01 Clinical Trial Optional)
(RFA-AI-19-024)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): July 26, 2019 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (U01 Clinical Trial Optional)
(RFA-AI-19-025)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): July 26, 2019 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)
(RFA-CA-19-034)
National Cancer Institute
Application Receipt Date(s): June 19, 2019, October 18, 2019, June 19, 2020, and October 18, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement . Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Limited Competition: Dental, Oral and Craniofacial Tissue Regeneration Consortium (U24 Clinical Trial Not Allowed)
(RFA-DE-19-010)
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): June 11, 2019 by 5:00 PM local time of applicant organization. No late applications will be accepted for this Funding Opportunity Announcement
Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional)
(RFA-DK-19-002)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): October 23, 2019 and June 2, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)
(RFA-DK-19-004)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): November 1, 2019 and July 1, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Kidney Technology Development Research Education Program (R25 Clinical Trial Not Allowed) (RFA-DK-19-006)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): August 6, 2019
Conduct Studies to Establish More Targeted Durations of Use for Certain Approved Antimicrobial New Animal Drugs in Food Animals (U01 Clinical Trial Required)
(RFA-FD-19-007)
Food and Drug Administration
Application Receipt Date(s): May 20, 2019, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
Implementation of the Animal Feed Regulatory Program Standards (U18 Clinical Trial Not Allowed) (RFA-FD-19-021)
Food and Drug Administration
Application Receipt Date(s): May 20, 2019, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
Medical Rehabilitation Research Resource (P2C Clinical Trial Optional)
(RFA-HD-20-004)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Center for Complementary and Integrative Health
National Institute of Biomedical Imaging and Bioengineering
National Institute on Deafness and Other Communication Disorders
National Institute of Neurological Disorders and Stroke
National Institute of Nursing Research
Application Receipt Date(s): June 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR) (UG3/UH3 Clinical Trial Optional)
(RFA-HL-20-003)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): May 17, 2019; October 1, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR) - Research Coordinating Center (RCC) (U24 Clinical Trial Not Allowed) (RFA-HL-20-004)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): May 17, 2019; October 1, 2019 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia and hemorrhagic conditions in low or lower-middle income countries (LLMICs) in Sub-Saharan Africa (UG3/UH3 Clinical Trial Optional)
(RFA-HL-20-009)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): May 20, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia and hemorrhagic conditions in low or lower-middle income countries (LLMICs) in Sub-Saharan Africa - Data Coordinating Center (DCC) (U24 Clinical Trial Not Allowed)
(RFA-HL-20-010)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): May 20, 2019 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Program Announcements

Administrative Supplement for Research on Bioethical Issues
(PA-19-217)
National Institutes of Health
John E. Fogarty International Center
National Center for Advancing Translational Sciences
National Cancer Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Neurological Disorders and Stroke
National Institute of Nursing Research
Application Receipt/Submission Date(s): May 13, 2019, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Advancing Manufacturing Processing and Control Strategies for Drug Substances and Drug Products (U01)- Clinical Trial Optional
(PAR-19-216)
Food and Drug Administration
Application Receipt/Submission Date(s): May 14, 2019, by 11:59 PM Eastern Time. April 4, 2020, by 11:59 PM Eastern Time. April 5, 2021, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34)
(PAR-19-218)
National Institute of General Medical Sciences
Application Receipt/Submission Date(s): May 21, 2019; May 21, 2020; May 21, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Maximizing Access to Research Careers (T34)
(PAR-19-219)
National Institute of General Medical Sciences
Application Receipt/Submission Date(s): May 21, 2019; May 21, 2020; May 21, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)
(PAR-19-220)
National Institute of Neurological Disorders and Stroke
National Center for Advancing Translational Sciences
Application Receipt/Submission Date(s): August 14, 2019; February 19, 2020; August 19, 2020; February 17, 2021; August 18, 2021; February 16, 2022 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.